– AIDS Committee of North Bay & Area - To assist and support all persons infected or affected by HIV/AIDS and/or Hepatitis C and to limit the spread of the viruses through eduction, awareness and outreach strategies.

Hep C Update

Watch “Deal With It” Doc on Hepatitis C in Canada

July 24th, 2015 at 10:12 am


Bang Albino Films today announced that it is making its documentary “Deal with it: Untold Stories of Hepatitis C in Canada” available digitally through iTunes.

Watch the trailer at the following link:

iTunes link:

The eye-opening film uncovers the country’s hidden hepatitis C epidemic. Today, 300,000 to 500,000 Canadians are estimated to have hepatitis C, a deadly virus that attacks the liver and can lead to liver cancer, transplantation, or death. Currently, hepatitis C causes more deaths and years of life lost than any other infectious disease in Canada, including HIV/AIDS. While the disease can affect anyone, Baby Boomers currently make up approximately 70% to 80% of hepatitis C cases in Canada, but many of them are unaware they have the virus.

“The difficulty with hepatitis C is that there are no symptoms that appear until it’s too late,” says Dr. Hemant Shah, Clinical Director, Francis Family Liver Clinic, University Health Network in Toronto, who was interviewed for the film. “It’s like you’re walking towards a cliff. You’re looking towards the horizon, but you don’t appreciate that the ground is about to give way and you feel perfectly fine as you walk towards that cliff.”

Thanks to the emergence of new drug therapies, hepatitis C (HCV) is now one of the few chronic diseases that, in most cases, can be cured – provided it’s caught and treated soon enough.

To get the word out to at-risk Canadians [] on the importance of getting tested and treated for HCV, the documentary’s producers have launched the “Deal with it / Dealt with it” awareness campaign in the lead up to World Hepatitis Day on July 28. The producers are asking anyone who has been touched by the disease to post a video or photo on Facebook and/or Twitter (#DealwithitHCV) wearing a “Deal with it / Dealt with it” wristband explaining how they are personally dealing with, or have dealt with, hepatitis C.

There is a huge public stigma surrounding hepatitis C that continues to prevent people from getting tested and treated for the disease, says Shah.

“The film does an excellent job of documenting the harm this prejudice causes individuals who have been diagnosed with HCV,” he added. “My hope is that THE CAMPAIGN will broaden the public’s understanding of this disease. I strongly encourage everyone who is battling, or who has beaten, hepatitis C to talk about it on social media and elsewhere on world hep day (July 28th) and beyond.”

Clinics and individuals can order “Deal with it / Dealt with it” wristbands and other campaign materials by or visiting

About Bang Albino Films

Toronto-based Bang Albino Films is a production company dedicated to creating short- and long-form documentaries on a variety of health and social issues affecting Canadians.

Help-4-Hep Offering New Mobile and Web App

May 20th, 2015 at 8:54 am

Scotch Plains, NJ & San Francisco, CA — May 19, 2015 – Help-4-Hep, a non-profit, peer-to-peer helpline where counselors work with patients to meet the challenges of hepatitis C, is launching today a new web and mobile app to bring its highly effective peer counselling services as well as a new self-care tool to more people affected by hepatitis C.

Hepatitis C is a silent and potentially deadly liver disease and a serious health issue affecting our population. For up to 80% of people who contract hepatitis C, the illness moves into a long-term phase called chronic hepatitis C. Up to 5 million people in  the United States today are living with chronic hepatitis C, and more people in the US die from the disease than from HIV. In recognition of the importance of creating awareness and educating the general public about this illness, this May is Hepatitis Awareness Month and today is Hepatitis Testing Day.

Help-4-Hep’s web and mobile app was developed in partnership with patient intelligence health solution provider, Self Care Catalysts (SCC). The Help-4-Hep app is part of Self Care Catalyst’s popular Health Storylines platform, leveraged by a wide number of patient communities to improve self-care and management of chronic conditions.

The app provides a suite of self-care tools for people living with chronic hepatitis C to help them better manage their illness and prepare for their treatment journey. It offers tools such as the ability to log lab tests, includes a food diary to help manage diet and nutrition and a mood tracker, allowing people living with hep C to chronicle their emotions and feelings. Individuals can also call the Help-4-Hep hotline directly from the app and discuss their condition with their counsellor.

Help 4 Hep aims to support more individuals living with hep C who are waiting for treatment. Physicians and nurses can also benefit from recommending the app to support their patients between visits.

“It’s incredibly important for people with chronic hepatitis C to take control of their health by tracking day to day routines and behaviors such as the amount of sleep and exercise they are getting and by eating well.  We are truly excited to be able to extend our network of support into the web and mobile world, so we can reach and help more people affected by hepatitis C,” says Dennis Simon, Managing Partner, Help-4-Hep.

Help-4-Hep’s web and mobile app is officially launching today on Hepatitis Testing Day. It is free and available on desktop, laptop, mobile and tablet devices. Interested users can sign-up on the Web, or download the app from the App Store? or from Google Play™. The app is available both in Canada and the US.

About Help-4-Hep

Help?4?Hep is a non-profit, peer-to-peer helpline where counselors work with patients to meet the challenges of hepatitis C head-on. Callers talk one-to-one with a real person, typically someone who’s had hepatitis C touch their own life. And they talk about the specifics of their particular situation. The phone call, support and information are all provided free of charge. Help-4-Hep is also the creator of the The Support Partnership – a network of nationally recognized nonprofits that have nearly 100 years of combined experience with peer helplines, hepatitis C support, education, testing, treatment and advocacy. For more information visit For counselling support call the Help-4-Hep hotline toll free at 877-Help-4-Hep.

About Self Care Catalysts
Self Care Catalysts is a patient solutions, intelligence and analytics company that enables healthcare innovation. We are committed to advocating for patients and consumers when it comes to healthcare decisions. Our belief is that when patients are informed, respected, and engaged, they make better choices. Better choices mean better health outcomes.

Our mission is to build innovative, patient-centered, and technology-driven self-care solutions that will enable patients to continue managing their care outside of the clinical setting.

May 19, 2015 | mHealthNews

Experimental Drug Combo Shows Promise Against Hep C

May 6th, 2015 at 1:54 pm


Tuesday, May 5, 2015 (HealthDay News) — Researchers have released yet another study finding impressive results for an experimental drug combo that aims to rid the body of infection with liver-damaging hepatitis C.

In this case, a combination of three drugs in the pipeline — daclatasvir, asunaprevir and beclabuvir — effectively cleared the virus in 93 percent of patients, according to new research from Duke University in Durham, N.C. All of the patients had already developed an infection-linked scarring of the liver known as cirrhosis.

None of these drugs has been approved by the U.S. Food and Drug Administration, but daclatasvir is currently under FDA review, according to a Duke news release.

One U.S. expert said the drug combination could be an additional advance against hepatitis C.

“This regimen is yet another all-oral treatment for the most common type of hepatitis C, which offers high cure rates with what appears to be an excellent tolerability profile,” said Dr. David Bernstein, chief of the division of hepatology at North Shore University Hospital in Manhasset, N.Y.

The study is published in the May 5 issue of the Journal of the American Medical Association.

As the researchers noted, for the past two decades treatment for hepatitis C has largely relied on interferon drugs, involving regular injections. The treatment, which can last for up to a year, is associated with severe flu-like symptoms, and many people discontinue the medication due to these unwanted side effects. Other patients are not able to take interferon because they are anemic, have a low platelet count or have another health issue.

The new study’s lead author explained: “Those with more advanced disease were unlikely to tolerate interferons, and many patients would decide against even getting treatment,” said Dr. Andrew Muir, chief of the division of gastroenterology at Duke. “For those who could tolerate it, it was only moderately effective,” he said in the news release.

However, since 2013, several drug companies have released new hepatitis C treatments that do not involve interferon drugs such as Sovaldi (sofosbuvir) or Harvoni (lepdipasvir-sofosbuvir). While very expensive, these drugs have also been very effective in safely ridding the body of hepatitis C.

“The development of interferon-free treatments has been a tremendous step forward in the standard of care,” Muir said. “These drugs are highly effective and well-tolerated by patients at all stages of liver disease.”

The new study was funded by drug maker Bristol-Myers Squibb. It involved 112 patients with cirrhosis related to hepatitis C that were never treated, as well as 90 who had undergone unsuccessful treatment for the condition.

The patients were treated between December 2013 and September 2014 at nearly 50 locations across the United States, Canada, France and Australia. All of the participants had genotype 1 hepatitis — a common strain of the hepatitis C virus in North America, Western Europe and Australia.

The three-drug regimen cleared the virus in 93 percent of patients with cirrhosis, according to a new study. The patients who benefited from the 12-week dose of three different drugs hadn’t received any previous treatment, the study’s authors noted.

The researchers found the drugs were less effective for those who’d been treated unsuccessfully in the past. The combination treatment eliminated the virus in 87 percent of these patients, suggesting their disease could be resistant to treatment.

Therapy was slightly more effective however, when these patients were given a fourth drug, ribavirin, which is commonly used to treat hepatitis C. After taking the additional drug, success rates jumped to 93 percent, according to the study.

Most of the patients had minor side effects. Nine of them developed serious health issues, but just three were considered related to the treatment.

Mary Elizabeth Dallas |  HealthDay Reporter

Timmins Man Hoping Fundraising Campaign Covers Life-Saving Hep C Meds

April 28th, 2015 at 11:19 am


A Timmins man with Hepatitis C says the only drug that can save him may take months to get and cost thousands of dollars.

Bill Desloges said there’s no guarantee the province will cover it, and is now turning to an online fundraising campaign for help.

Desloges, 59, said he went numb when found out his Hepatitis C had taken a turn for the worst.

Hepatitis C is a chronic viral liver disease, and Desloges was diagnosed about 12 years ago. He went on treatment, but it didn’t work.

He recently went for testing in Sudbury and found out he was in stage four, the final stage of the disease.

Desloges said his only hope for a cure is to get a new drug on the market called Harvoni, a pill he’d have to take each day for 24 weeks, at a cost of upwards of $140,000.

“I just don’t understand why [or] how a medication could be so expensive,” he said.

Desloges said he could start paying for a few of the pills, but said he has to buy the entire treatment plan at once or else the drugs are ineffective.

He applied for re-imbursement from the province, but there’s no guarantee how much he’ll get.

His doctor, Kim Tilbe predicts it will take months before Desloges finds out if he’ll get the funding.

Tilbe said more than 600 applications for the drug have been made in the province, including 50 in Sudbury.

“I think that the same frustrations that their patients have, physicians who have to do all the paperwork have the same concerns,” he said.

In an e-mail to the CBC, the Ministry of Health said the current turnaround time to review rush drug requests is about 21 business days. The ministry added it recognizes that a 21-business day turnaround is not acceptable, and has several business improvement initiatives underway.

It added the state of a patient is taken into account when the request is being reviewed.

Tilbe said so far, one of his patients, the first in the province, has had the drug approved to be paid for.

But Desloges said he and his family can’t wait any longer.

His niece, Paige Desloges Baril, has started a GoFundMe campaign to raise the money that’s needed for his treatment.

Paige Desloges Baril has started a Go Fund Me Campaign for her uncle’s Hepatitis C treatment. (Nael Shiab)

“I was lost for words,” Desloges said, when he found out the campaign had been set up.

“I didn’t expect it. I just came out of left field. She’s such a great person.”

Desloges added the online fundraiser has prompted other acts of kindness in the community to support him, including fundraisers and raffle tickets being sold to help.

“The support is just amazing,” he said.

“I know in my heart that if I don’t get it, they’ve tried. That’s all I’m asking, that people try.” | Nael Shiab

Health Canada Warns of Side-Effects From Hepatitis C-Heart Drug Combo

April 7th, 2015 at 1:23 pm


TORONTO – Health Canada is warning that a drug combination involving new hepatitis C drugs can lead to a seriously slow heart rate and should be avoided.

Nine cases of the reaction have been reported, including two in Canada.

Of those nine cases, one was fatal and three others required insertion of a pacemaker.

The department says people should not take new hepatitis C drugs Harvoni or Sovaldi in combination with another antiviral drug and a heart rhythm drug called amiodarone.

Health Canada is working with Gilead Sciences to update the warnings on the packaging of Sovaldi and Harvoni.

Symptoms of the reaction include fainting or nearly fainting, dizziness or lightheadedness, malaise and weakness, shortness of breath and chest pain.

Canadian Press | April 6, 2015